|本期目录/Table of Contents|

[1]彭道泉.IMPROVE-IT 研究化解“强化降脂”与“强化他汀”之争[J].慢性病学杂志,2015,(03):248-250.
点击复制

IMPROVE-IT 研究化解“强化降脂”与“强化他汀”之争(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2015年03期
页码:
248-250
栏目:
血脂专栏
出版日期:
2015-06-16

文章信息/Info

Title:
-
作者:
彭道泉
中南大学湘雅二医院心内科，长沙410011
Author(s):
-
关键词:
IMPROVE-IT; 强化降脂; 强化他汀
Keywords:
-
分类号:
R541
DOI:
-
摘要:
-
Abstract:
-

参考文献/References:

[1] Cannon CP, Blazing MA, Giugliano RP,et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes[J]．N Engl J Med,2015Jun3, [Epub ahead ofprint]PubMed PMID:26039521.
[2] Baigent C, Keech A, Kearney PM,et al.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from90,056participants in14randomised trials of statins [J]．Lancet,2005,366:1267–1278.
[3] Cholesterol Treatment Trialists C, Baigent C, Blackwell L,et al. Efficacy and safety of more intensive lowering of LDL cho? lesterol: a meta-analysis of data from 170,000participants in 26randomised trials[J]．Lancet,2010,376:1670–1681.
[4] Laufs U, Descamps OS, Catapano AL,et al. Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention.[J]．EurHeartJ,2014,35(30):1996-2000.
[5] HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R,et al. Effects of extended-release niacin with laropiprant in high-risk patients[J]．N EnglJ Med,2014,371(3):203-12.
[6] Masana L,cabre A,Plana N.HPS2-THRIVE results:bad for niacin/laropiprant,good for ezetimibe[J]．Atherosderosis, 2013,229(2):449-450.

备注/Memo

备注/Memo:
作者简介：彭道泉，博士，博士生导师，主要从事血脂与 动脉粥样硬化研究工作 通信作者：彭道泉，E-mail：pengdq@hotmail.com
更新日期/Last Update: 2015-06-15